Circulating Tumor Cell Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510245619

Publication Date:

October 21, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Circulating Tumor Cell Testing was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Circulating Tumor Cell Testing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Circulating Tumor Cell Testing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Circulating Tumor Cell Testing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Circulating Tumor Cell Testing include Advanced Cell Diagnostics, Inc., Aviva Biosciences, Cynvenio Biosystems, Inc., ApoCell, Biocept Inc., Qiagen, MiltenyiBiotec, Clearbridge Biomedics Pte Ltd and Menarini Silicon Biosystems, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cell Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Circulating Tumor Cell Testing by region & country, by Type, and by Application.
The Circulating Tumor Cell Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cell Testing.
Market Segmentation
By Company
Advanced Cell Diagnostics, Inc.
Aviva Biosciences
Cynvenio Biosystems, Inc.
ApoCell
Biocept Inc.
Qiagen
MiltenyiBiotec
Clearbridge Biomedics Pte Ltd
Menarini Silicon Biosystems
Segment by Type:
Lmmunocytochemical Technology for Circulating Tumor Cell Testing
Molecular(rna) Based Technology for Circulating Tumor Cell Testing
Xenotransplantation Technology for Circulating Tumor Cell Testing
Others
Segment by Application
Hospital
Biological Testing Agency
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Circulating Tumor Cell Testing manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Circulating Tumor Cell Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Circulating Tumor Cell Testing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Circulating Tumor Cell Testing Product Introduction
1.2 Global Circulating Tumor Cell Testing Market Size Forecast
1.3 Circulating Tumor Cell Testing Market Trends & Drivers
1.3.1 Circulating Tumor Cell Testing Industry Trends
1.3.2 Circulating Tumor Cell Testing Market Drivers & Opportunity
1.3.3 Circulating Tumor Cell Testing Market Challenges
1.3.4 Circulating Tumor Cell Testing Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Circulating Tumor Cell Testing Players Revenue Ranking (2023)
2.2 Global Circulating Tumor Cell Testing Revenue by Company (2019-2024)
2.3 Key Companies Circulating Tumor Cell Testing Manufacturing Base Distribution and Headquarters
2.4 Key Companies Circulating Tumor Cell Testing Product Offered
2.5 Key Companies Time to Begin Mass Production of Circulating Tumor Cell Testing
2.6 Circulating Tumor Cell Testing Market Competitive Analysis
2.6.1 Circulating Tumor Cell Testing Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Circulating Tumor Cell Testing Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cell Testing as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Lmmunocytochemical Technology for Circulating Tumor Cell Testing
3.1.2 Molecular(rna) Based Technology for Circulating Tumor Cell Testing
3.1.3 Xenotransplantation Technology for Circulating Tumor Cell Testing
3.1.4 Others
3.2 Global Circulating Tumor Cell Testing Sales Value by Type
3.2.1 Global Circulating Tumor Cell Testing Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Circulating Tumor Cell Testing Sales Value, by Type (2019-2030)
3.2.3 Global Circulating Tumor Cell Testing Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Biological Testing Agency
4.1.3 Others
4.2 Global Circulating Tumor Cell Testing Sales Value by Application
4.2.1 Global Circulating Tumor Cell Testing Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Circulating Tumor Cell Testing Sales Value, by Application (2019-2030)
4.2.3 Global Circulating Tumor Cell Testing Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Circulating Tumor Cell Testing Sales Value by Region
5.1.1 Global Circulating Tumor Cell Testing Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Circulating Tumor Cell Testing Sales Value by Region (2019-2024)
5.1.3 Global Circulating Tumor Cell Testing Sales Value by Region (2025-2030)
5.1.4 Global Circulating Tumor Cell Testing Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Circulating Tumor Cell Testing Sales Value, 2019-2030
5.2.2 North America Circulating Tumor Cell Testing Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Circulating Tumor Cell Testing Sales Value, 2019-2030
5.3.2 Europe Circulating Tumor Cell Testing Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Circulating Tumor Cell Testing Sales Value, 2019-2030
5.4.2 Asia Pacific Circulating Tumor Cell Testing Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Circulating Tumor Cell Testing Sales Value, 2019-2030
5.5.2 South America Circulating Tumor Cell Testing Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Circulating Tumor Cell Testing Sales Value, 2019-2030
5.6.2 Middle East & Africa Circulating Tumor Cell Testing Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Circulating Tumor Cell Testing Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Circulating Tumor Cell Testing Sales Value
6.3 United States
6.3.1 United States Circulating Tumor Cell Testing Sales Value, 2019-2030
6.3.2 United States Circulating Tumor Cell Testing Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Circulating Tumor Cell Testing Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Circulating Tumor Cell Testing Sales Value, 2019-2030
6.4.2 Europe Circulating Tumor Cell Testing Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Circulating Tumor Cell Testing Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Circulating Tumor Cell Testing Sales Value, 2019-2030
6.5.2 China Circulating Tumor Cell Testing Sales Value by Type (%), 2023 VS 2030
6.5.3 China Circulating Tumor Cell Testing Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Circulating Tumor Cell Testing Sales Value, 2019-2030
6.6.2 Japan Circulating Tumor Cell Testing Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Circulating Tumor Cell Testing Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Circulating Tumor Cell Testing Sales Value, 2019-2030
6.7.2 South Korea Circulating Tumor Cell Testing Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Circulating Tumor Cell Testing Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Circulating Tumor Cell Testing Sales Value, 2019-2030
6.8.2 Southeast Asia Circulating Tumor Cell Testing Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Circulating Tumor Cell Testing Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Circulating Tumor Cell Testing Sales Value, 2019-2030
6.9.2 India Circulating Tumor Cell Testing Sales Value by Type (%), 2023 VS 2030
6.9.3 India Circulating Tumor Cell Testing Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Advanced Cell Diagnostics, Inc.
7.1.1 Advanced Cell Diagnostics, Inc. Profile
7.1.2 Advanced Cell Diagnostics, Inc. Main Business
7.1.3 Advanced Cell Diagnostics, Inc. Circulating Tumor Cell Testing Products, Services and Solutions
7.1.4 Advanced Cell Diagnostics, Inc. Circulating Tumor Cell Testing Revenue (US$ Million) & (2019-2024)
7.1.5 Advanced Cell Diagnostics, Inc. Recent Developments
7.2 Aviva Biosciences
7.2.1 Aviva Biosciences Profile
7.2.2 Aviva Biosciences Main Business
7.2.3 Aviva Biosciences Circulating Tumor Cell Testing Products, Services and Solutions
7.2.4 Aviva Biosciences Circulating Tumor Cell Testing Revenue (US$ Million) & (2019-2024)
7.2.5 Aviva Biosciences Recent Developments
7.3 Cynvenio Biosystems, Inc.
7.3.1 Cynvenio Biosystems, Inc. Profile
7.3.2 Cynvenio Biosystems, Inc. Main Business
7.3.3 Cynvenio Biosystems, Inc. Circulating Tumor Cell Testing Products, Services and Solutions
7.3.4 Cynvenio Biosystems, Inc. Circulating Tumor Cell Testing Revenue (US$ Million) & (2019-2024)
7.3.5 ApoCell Recent Developments
7.4 ApoCell
7.4.1 ApoCell Profile
7.4.2 ApoCell Main Business
7.4.3 ApoCell Circulating Tumor Cell Testing Products, Services and Solutions
7.4.4 ApoCell Circulating Tumor Cell Testing Revenue (US$ Million) & (2019-2024)
7.4.5 ApoCell Recent Developments
7.5 Biocept Inc.
7.5.1 Biocept Inc. Profile
7.5.2 Biocept Inc. Main Business
7.5.3 Biocept Inc. Circulating Tumor Cell Testing Products, Services and Solutions
7.5.4 Biocept Inc. Circulating Tumor Cell Testing Revenue (US$ Million) & (2019-2024)
7.5.5 Biocept Inc. Recent Developments
7.6 Qiagen
7.6.1 Qiagen Profile
7.6.2 Qiagen Main Business
7.6.3 Qiagen Circulating Tumor Cell Testing Products, Services and Solutions
7.6.4 Qiagen Circulating Tumor Cell Testing Revenue (US$ Million) & (2019-2024)
7.6.5 Qiagen Recent Developments
7.7 MiltenyiBiotec
7.7.1 MiltenyiBiotec Profile
7.7.2 MiltenyiBiotec Main Business
7.7.3 MiltenyiBiotec Circulating Tumor Cell Testing Products, Services and Solutions
7.7.4 MiltenyiBiotec Circulating Tumor Cell Testing Revenue (US$ Million) & (2019-2024)
7.7.5 MiltenyiBiotec Recent Developments
7.8 Clearbridge Biomedics Pte Ltd
7.8.1 Clearbridge Biomedics Pte Ltd Profile
7.8.2 Clearbridge Biomedics Pte Ltd Main Business
7.8.3 Clearbridge Biomedics Pte Ltd Circulating Tumor Cell Testing Products, Services and Solutions
7.8.4 Clearbridge Biomedics Pte Ltd Circulating Tumor Cell Testing Revenue (US$ Million) & (2019-2024)
7.8.5 Clearbridge Biomedics Pte Ltd Recent Developments
7.9 Menarini Silicon Biosystems
7.9.1 Menarini Silicon Biosystems Profile
7.9.2 Menarini Silicon Biosystems Main Business
7.9.3 Menarini Silicon Biosystems Circulating Tumor Cell Testing Products, Services and Solutions
7.9.4 Menarini Silicon Biosystems Circulating Tumor Cell Testing Revenue (US$ Million) & (2019-2024)
7.9.5 Menarini Silicon Biosystems Recent Developments
8 Industry Chain Analysis
8.1 Circulating Tumor Cell Testing Industrial Chain
8.2 Circulating Tumor Cell Testing Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Circulating Tumor Cell Testing Sales Model
8.5.2 Sales Channel
8.5.3 Circulating Tumor Cell Testing Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Advanced Cell Diagnostics, Inc.
Aviva Biosciences
Cynvenio Biosystems, Inc.
ApoCell
Biocept Inc.
Qiagen
MiltenyiBiotec
Clearbridge Biomedics Pte Ltd
Menarini Silicon Biosystems

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂